Literature DB >> 11447149

Facilitated intranasal induction of mucosal and systemic immunity to mutans streptococcal glucosyltransferase peptide vaccines.

D J Smith1, W F King, L A Barnes, D Trantolo, D L Wise, M A Taubman.   

Abstract

Synthetic peptide vaccines which are derived from functional domains of Streptococcus mutans glucosyltransferases (GTF) have been shown to induce protective immunity in Sprague-Dawley rats after subcutaneous injection in the salivary gland region. Since mucosal induction of salivary immunity would be preferable in humans, we explored methods to induce mucosal antibody in the rat to the GTF peptide vaccines HDS and HDS-GLU after intranasal administration. Several methods of facilitation of the immune response were studied: the incorporation of peptides in bioadhesive poly(D,L-lactide-coglycolide) (PLGA) microparticles, the use of monoepitopic (HDS) or diepitopic (HDS-GLU) peptide constructs, or the use of mucosal adjuvants. Salivary immunoglobulin A (IgA) responses were not detected after intranasal administration of diepitopic HDS-GLU peptide constructs in alum or after incorporation into PLGA microparticles. However, significant primary and secondary salivary IgA and serum IgG antibody responses to HDS were induced in all rats when cholera holotoxin (CT) or a detoxified mutant Escherichia coli heat-labile enterotoxin (R192G LT) were intranasally administered with HDS peptide constructs in PLGA. Coadministration of LT with HDS resulted in predominantly IgG2a responses in the serum, while coadministration with CT resulted in significant IgG1 and IgG2a responses to HDS. Serum IgG antibody, which was induced to the HDS peptide construct by coadministration with these adjuvants, also bound intact mutans streptococcal GTF in an enzyme-linked immunosorbent assay and inhibited its enzymatic activity. Thus, immune responses which are potentially protective for dental caries can be induced to peptide-based GTF vaccines after mucosal administration if combined with the CT or LT R192G mucosal adjuvant.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11447149      PMCID: PMC98563          DOI: 10.1128/IAI.69.8.4767-4773.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  54 in total

1.  Isolation of key amino acid residues at the N-terminal end of the core region Streptococcus downei glucansucrase, GTF-I.

Authors:  V Monchois; M Vignon; R R Russell
Journal:  Appl Microbiol Biotechnol       Date:  1999-11       Impact factor: 4.813

2.  Requirement of B7 costimulation for Th1-mediated inflammatory bone resorption in experimental periodontal disease.

Authors:  T Kawai; R Eisen-Lev; M Seki; J W Eastcott; M E Wilson; M A Taubman
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

3.  Three-dimensional modelling of the catalytic domain of Streptococcus mutans glucosyltransferase GtfB.

Authors:  Y W Tsai; J S Chia; Y Y Shiau; H C Chou; Y C Liaw; K L Lou
Journal:  FEMS Microbiol Lett       Date:  2000-07-01       Impact factor: 2.742

4.  Antibody to glucosyltransferase induced by synthetic peptides associated with catalytic regions of alpha-amylases.

Authors:  D J Smith; R L Heschel; W F King; M A Taubman
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

5.  Mutagenesis of asp-569 of glucosyltransferase I glucansucrase modulates glucan and oligosaccharide synthesis.

Authors:  V Monchois; M Vignon; R R Russell
Journal:  Appl Environ Microbiol       Date:  2000-05       Impact factor: 4.792

6.  Involvement of Gln937 of Streptococcus downei GTF-I glucansucrase in transition-state stabilization.

Authors:  V Monchois; M Vignon; P C Escalier; B Svensson; R R Russell
Journal:  Eur J Biochem       Date:  2000-07

7.  Coimmunization with complementary glucosyltransferase peptides results in enhanced immunogenicity and protection against dental caries.

Authors:  M A Taubman; D J Smith; C J Holmberg; J W Eastcott
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

8.  Structure and possible catalytic residues of Taka-amylase A.

Authors:  Y Matsuura; M Kusunoki; W Harada; M Kakudo
Journal:  J Biochem       Date:  1984-03       Impact factor: 3.387

Review 9.  New approaches to mucosal immunization.

Authors:  L Cárdenas-Freytag; E Cheng; A Mirza
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

10.  Adjuvant activity of a nontoxic mutant of Escherichia coli heat-labile enterotoxin on systemic and mucosal immune responses elicited against a heterologous antigen carried by a live Salmonella enterica serovar Typhimurium vaccine strain.

Authors:  H C Guillobel; J I Carinhanha; L Cárdenas; J D Clements; D F de Almeida; L C Ferreira
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

View more
  4 in total

1.  Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2.

Authors:  Manuel Vilanova; Luzia Teixeira; Iris Caramalho; Egídio Torrado; Andreia Marques; Pedro Madureira; Adília Ribeiro; Paula Ferreira; Miguel Gama; Jocelyne Demengeot
Journal:  Immunology       Date:  2004-03       Impact factor: 7.397

2.  Mutans streptococcal infection induces salivary antibody to virulence proteins and associated functional domains.

Authors:  R D Nogueira; W F King; G Gunda; S Culshaw; M A Taubman; R O Mattos-Graner; D J Smith
Journal:  Infect Immun       Date:  2008-05-12       Impact factor: 3.441

3.  Chitosan-coated poly(lactic-co-glycolic) acid nanoparticles as an efficient delivery system for Newcastle disease virus DNA vaccine.

Authors:  Kai Zhao; Yang Zhang; Xiaoyan Zhang; Ci Shi; Xin Wang; Xiaohua Wang; Zheng Jin; Shangjin Cui
Journal:  Int J Nanomedicine       Date:  2014-09-30

Review 4.  Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins.

Authors:  Terry D Connell
Journal:  Expert Rev Vaccines       Date:  2007-10       Impact factor: 5.217

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.